Adjuvant liver infusion after colorectal cancer liver surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a treatment given directly into the liver after surgery to remove colorectal cancer that has spread to the liver. The goal is to see if this treatment lowers the chance of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You had surgery to remove the colorectal tumor and liver metastases within the past 12 weeks, and no cancer remains.
- You are generally active (able to do daily activities without help).
- You have adequate blood, kidney, and liver function (basic lab tests will confirm this).
- You are not pregnant or breastfeeding, and you agree to use effective birth control during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving chemotherapy directly into the liver after surgery can lower the chance of cancer coming back. It is for people who had multiple liver tumors removed and whose cancer did not grow during pre-surgery chemo.
This trial tests a combination of liposomal irinotecan, two chemotherapy drugs (leucovorin and 5-fluorouracil), and bevacizumab as a second-line treatment for people with colorectal cancer that has spread and cannot be removed by surgery.
This trial studies a “liver-first” approach for colorectal cancer that has spread mainly to the liver, to see if it can help more people have the tumor(s) removed or treated. You may be eligible if your liver involvement is too extensive for immediate surgery but could become treatable after a specific plan.
This trial tests whether adding two targeted drugs (serplulimab and bevacizumab) to standard chemotherapy before surgery can improve outcomes for people with colorectal cancer that has spread to the liver. It is for those whose cancer has certain genetic features and is considered resectable.
This trial tests a strong chemotherapy combination given directly into the liver's blood supply (called HAIC) for people whose colorectal cancer has spread only to the liver and cannot be removed with surgery yet. The goal is to shrink the liver tumors enough so they can be surgically removed.
This trial tests a special type of chemotherapy (hepatic artery infusion) for people with cancers that have spread to the liver, such as colorectal cancer or bile duct cancer (intrahepatic cholangiocarcinoma). It studies whether delivering this treatment partly at a community center and partly at a university hospital is safe and feasible.
Hear when a new Colorectal Cancer Liver Metastases (CRLM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.